Dogwood Therapeutics Q2 FY26 net loss widens to $11.5 million

• Dogwood Therapeutics posted a Q2 net loss attributable to common stockholders of $11.5 million, or $0.34 a share.
• R&D expense rose to $3.25 million from $2.57 million a year earlier, due to higher Halneuron Phase 2b CINP study costs.
• G&A expense increased to $1.63 million from $1.35 million, on higher salaries and related personnel costs.
• Booked a $6.7 million net non-cash impairment charge tied to goodwill and IPR&D, including a $9.2 million IPR&D impairment.
• Cash totaled $9.61 million; Halneuron Phase 2b CINP trial had 217 patients enrolled, with top-line results expected in fall 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130830PRIMZONEFULLFEED9809209) on August 13, 2026, and is solely responsible for the information contained therein.